Eloxx Pharmaceuticals, Inc.
ELOX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001035354
No open-market purchases or sales by Eloxx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $34.7M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Eloxx Pharmaceuticals, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- −13 vs. Q3 2022
- Shares held
- 262.0K
- −54.7K (−17.3%) vs. Q3 2022Converted for a 1-for-40 split
- Total value
- $476.7K
- −$1.66M (−77.7%) vs. Q3 2022
- New holders
- 3
- 3 more added
- Sold out
- 16
- 5 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ELOX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 22 | $34.7M |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 1 | $0 |
| Q2 2024 | 1 | $43 |
| Q1 2024 | 1 | $62 |
| Q4 2023 | 4 | $109.0K |
| Q3 2023 | 18 | $2.50M |
| Q2 2023 | 16 | $924.2K |
| Q1 2023 | 19 | $671.5K |
| Q4 2022 | 19 | $476.7K |
| Q3 2022 | 32 | $2.14M |
| Q2 2022 | 32 | $3.51M |
| Q1 2022 | 36 | $8.42M |
| Q4 2021 | 39 | $11.7M |
| Q3 2021 | 41 | $26.0M |
| Q2 2021 | 47 | $33.2M |
| Q1 2021 | 38 | $28.7M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Eloxx Pharmaceuticals, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Menora Mivtachim Holdings Ltd. | 52,355 | $95.3K | 0.00% | 00.0% | UnchangedConverted for a 1-for-40 split |
| Vanguard Group Inc | 40,413 | $73.6K | 0.00% | −27,200−40.2% | ReducedConverted for a 1-for-40 split |
| American Financial Group Inc | 37,000 | $67.0K | 0.02% | 00.0% | UnchangedConverted for a 1-for-40 split |
| Harel Insurance Investments & Financial Services Ltd. | 29,410 | $54.0K | 0.00% | 00.0% | UnchangedConverted for a 1-for-40 split |
| Silverarc Capital Management, LLC | 26,876 | $48.9K | 0.02% | −586−2.1% | ReducedConverted for a 1-for-40 split |
| Altshuler Shaham Ltd | 25,123 | $45.7K | 0.00% | 00.0% | UnchangedConverted for a 1-for-40 split |
| Geode Capital Management, LLC | 20,196 | $36.0K | 0.00% | 00.0% | UnchangedConverted for a 1-for-40 split |
| Clal Insurance Enterprises Holdings Ltd | 14,626 | $27.0K | 0.00% | 00.0% | UnchangedConverted for a 1-for-40 split |
| BlackRock Inc. | 8,890 | $16.2K | 0.00% | 00.0% | UnchangedConverted for a 1-for-40 split |
| Tower Research Capital LLC (TRC) | 3,789 | $7.00K | 0.00% | +3,307+686.1% | AddedConverted for a 1-for-40 split |
| Bank of America Corp | 1,949 | $3.55K | 0.00% | +498+34.4% | AddedConverted for a 1-for-40 split |
| Wells Fargo & Company | 1,167 | $2.12K | 0.00% | 00.0% | UnchangedConverted for a 1-for-40 split |
| UBS Group AG | 123 | $224 | 0.00% | +123 | New |
| Morgan Stanley | 80 | $146 | 0.00% | +1+0.8% | AddedConverted for a 1-for-40 split |
| Meeder Asset Management Inc | 15 | $27 | 0.00% | −1−4.3% | ReducedConverted for a 1-for-40 split |
| Group One Trading, L.P. | 4 | $7 | 0.00% | −0−10.6% | ReducedConverted for a 1-for-40 split |
| NewSquare Capital LLC | 1 | $2 | 0.00% | +1 | New |
| JPMorgan Chase & Co | 1 | $0 | 0.00% | −1−54.0% | ReducedConverted for a 1-for-40 split |
| Royal Bank of Canada | 14 | $0 | 0.00% | +14 | New |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −5,623−100.0% | Sold outConverted for a 1-for-40 split |
| State Street Corp | 0 | $0 | 0.00% | −4,749−100.0% | Sold outConverted for a 1-for-40 split |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −3,635−100.0% | Sold outConverted for a 1-for-40 split |
| Atom Investors LP | 0 | $0 | 0.00% | −3,603−100.0% | Sold outConverted for a 1-for-40 split |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −3,338−100.0% | Sold outConverted for a 1-for-40 split |
| Vanguard Capital Wealth Advisors | 0 | $0 | 0.00% | −3,175−100.0% | Sold outConverted for a 1-for-40 split |
| Northern Trust Corp | 0 | $0 | 0.00% | −3,092−100.0% | Sold outConverted for a 1-for-40 split |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −1,466−100.0% | Sold outConverted for a 1-for-40 split |
| National Asset Management, Inc. | 0 | $0 | 0.00% | −963−100.0% | Sold outConverted for a 1-for-40 split |
| Virtu Financial LLC | 0 | $0 | 0.00% | −373−100.0% | Sold outConverted for a 1-for-40 split |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −463−100.0% | Sold outConverted for a 1-for-40 split |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −309−100.0% | Sold outConverted for a 1-for-40 split |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −12−100.0% | Sold outConverted for a 1-for-40 split |
| Credit Suisse AG | 0 | $0 | 0.00% | −0−100.0% | Sold outConverted for a 1-for-40 split |
| National Bank of Canada | 0 | $0 | 0.00% | −0−100.0% | Sold outConverted for a 1-for-40 split |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −12−100.0% | Sold outConverted for a 1-for-40 split |